Upsher-Smith Laboratories, LLC announced the approval of a supplemental New Drug Application for its Morphine Sulfate product, broadening its portfolio of FDA-approved opioid treatments. This development strengthens the company's market share in the oral pain management sector as the legacy market continues to navigate shifts in patient access policies.